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Abstract
Background: Telemedicine use is increasing in many specialties, but its impact on clinical outcomes in infectious
diseases has not been systematically studied and reviewed. The proposed systematic review will evaluate the
current evidence regarding the effect of telemedicine infectious diseases consultation on a range of clinical
outcomes, including mortality, hospital readmission, antimicrobial use, and cost.
Method/design: Standard systematic review methodology will be used, with searches of Ovid MEDLINE 1946-,
https://embase.com/ 1947-, Scopus 1823-, Cochrane Database of Systematic Reviews (CDSR), Cochrane Central
Register of Controlled Trials (CENTRAL), and https://clinicaltrials.gov/ 1997-. There will be no restriction on language
or year of publication. The primary outcome will be 30-day all-cause mortality and secondary outcomes will include
readmission within 30 days after discharge from an initial hospitalization with an infection, patient compliance/
adherence, patient satisfaction, cost or cost effectiveness, length of hospital stay, antimicrobial use, and
antimicrobial stewardship. Bias will be assessed using standard Cochrane methodologies. Data will be grouped by
outcome and narratively synthesized. Meta-analysis will be performed for outcomes with clinical or methodological
homogeneity. The systematic review and meta-analysis will be registered through PROSPERO. Pre-planned
subgroup analyses will be detailed.
Discussion: A number of studies have documented the feasibility of telemedicine for infectious diseases, but a
synthesis of clinical outcomes data with telemedicine infectious diseases consultation has not been performed. This
systematic review will analyze many clinical outcomes of telemedicine infectious diseases consultation. The findings
of this study will add to established literature about feasibility of telemedicine consultation by synthesizing the
evidence for clinical effectiveness.
Systematic review registration: PROSPERO CRD42018105225
Keywords: Systematic review, Telemedicine, Infectious diseases, Consultation, Mortality, Telehealth, Cost,
Antimicrobial
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Background
According to recent estimates, infectious diseases may
be the third leading cause of death in the USA [1].
Underserved or economically disadvantaged areas often
do not have access to infectious diseases (ID) physicians
(up to 45% of US hospitals) to help treat these infections
[2]. Consultation with ID physicians has been shown to sig-
nificantly reduce mortality for a range of infections [3, 4].
Providing access to ID expertise in underserved areas could
substantially reduce mortality and improve other clinical
outcomes. The field of ID has difficulty recruiting new phy-
sicians, with 51% of fellowship programs not filling in 2015
[5, 6]. With this shortage of ID physicians, it is not feasible
for remote locations to employ a dedicated ID physician.
Telemedicine could efficiently and cost-effectively expand
ID expertise to underserved areas. Telemedicine reduces
mortality in progressive and intensive care units and in very
low-birth weight infants [7–9], but there has been no syn-
thesis of evidence for the use of telemedicine for infectious
diseases. Our systematic review and meta-analysis will ad-
dress this deficiency by summarizing the evidence for clin-
ical effectiveness of telemedicine for infectious diseases.
Methods/design
Aim
The aim is to assess the effectiveness of telemedicine for
all patients with infectious diseases for a range of clinical
outcomes (enumerated below) as compared to either (1)
no infectious diseases consultation or (2) other modal-
ities of infectious disease consultation (e.g., in-person).
The aim will be achieved by conducting a systematic re-
view of studies in which telemedicine is utilized to study
any of the following clinical outcomes: 30-day all-cause
mortality, readmission within 30 days after discharge
from an initial hospitalization with an infection, patient
compliance/adherence, patient satisfaction, cost or cost
effectiveness, length of hospital stay, antimicrobial use,
and antimicrobial stewardship.
Standard systematic review methodology will be used,
with searches of Ovid MEDLINE 1946-, Embase.com
1947-, Scopus 1823-, Cochrane Database of Systematic
Reviews (CDSR), Cochrane Central Register of Con-
trolled Trials (CENTRAL), and Clinicaltrials.gov 1997-.
The protocol has been registered with the international
prospective register of systematic reviews (PROSPERO),
in accordance with PRISMA-P guidelines [10].
The search strategy includes terms for infection, tele-
health, and clinical outcomes and has been submitted to
PROSPERO in advance of study initiation. The full search
strategy will be released upon completion of the study. Ar-
ticles included in the final systematic review and meta-
analysis will be reviewed for other references that were
missed by the search strategy. Systematic reviews will also
be used to determine if all relevant primary studies have
been identified.
There will be no language or year of publication re-
strictions. Translation of non-English language articles
will be undertaken, either in part or in full, as required.
Conference abstracts will be excluded if sufficient out-
come and bias data cannot be extracted from the ab-
stract. Duplicate records will be purged. REDCap will be
used by the authors for data entry.
Selection criteria
In order for studies to be included in the final analysis,
they must meet all of the following inclusion criteria:
 Populations/participants must receive telemedicine
consultation for an infectious disease or be a control
arm of a study of telemedicine consultation for an
infectious disease
 Report one or more of the following clinical
outcomes: 30-day mortality after an infection, re-
admission within 30 days after discharge from the
initial hospitalization with an infection, patient com-
pliance/adherence, patient satisfaction, cost or cost
effectiveness, length of stay, antimicrobial use, and
antimicrobial stewardship
Studies will be excluded if any of the following condi-
tions are met:
 Case report only
 Conference abstracts in which insufficient detail is
provided to ascertain outcomes or determine the
possibility of bias
 Do not have one of outcomes of interest measured
 If a study involves consultation for multiple
conditions, the study will be excluded if outcomes
specifically for infectious diseases cannot be
separated from outcomes for other conditions
 No control group
 Non-interventional studies including, but not
limited to, reviews, protocols, editorials, letters to
the editor, and viewpoints
Definitions
Telemedicine will be defined as remote clinical services
administered using a technological medium. This in-
cludes face-to-face video chat (physician-to-physician or
physician-to-patient), voice chat after review of elec-
tronic health records, or electronic health record docu-
mentation after remote chart review without direct voice
or video contact with physician or patient.
Where the data are available, we will categorize hos-
pital readmissions as being related or unrelated to infec-
tion. For the outcome of cost effectiveness, we are
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specifically referring to a comparison of cost between
telemedicine and usual care (i.e., control) groups for an
episode of infection. Antibiotic stewardship will be
quantified as either antibiotic costs or antibiotic appro-
priateness, as judged by the authors of the individual
studies.
Selection process
Titles and abstracts will be reviewed by JPB, with studies
excluded that obviously do not meet inclusion criteria or
meet any exclusion criteria. After the initial title and ab-
stract review, in a blinded fashion, JPB and GAC will re-
view the relevant full-text articles to determine their
relevance to the research question. Any disputes on po-
tential study inclusion will be settled by a third reviewer
(SAF—also blinded). Details of the reasons for exclusion
at the full-text stage will be recorded and reported.
Study selection will be documented using a PRISMA
flow diagram.
Data extraction
In a blinded fashion, two authors (JPB and GAC) will in-
dependently extract data from the included articles. Dis-
crepancies will be adjudicated by a third reviewer (SAF).
Data will be entered into a data extraction form through
REDCap. Data to be extracted include study quality,
clinical or system-level outcome tracked, percent change
or proportion experiencing each clinical outcome, and
numbers of patients in all intervention arms as well as
percent receiving ID consults, age group, consultant spe-
cialty, type of telemedicine, study location, whether in-
fection was confirmed by laboratory results, and type
and risk of bias.
Quality assessment
Risk of bias will be reviewed by two reviewers (JPB and
GAC) in a blinded fashion. Any disputes on potential
bias will be settled by a third reviewer (SAF—also
blinded). Bias determination will be guided by the ap-
plicable portions of the Cochrane Consumers & Com-
munication Review Group Study Quality Guide or
Newcastle-Ottawa scale [11, 12].
Analysis
We plan to analyze primary and secondary outcomes
with a quantitative synthesis for all participants, but also
plan to analyze by age (children < 18 versus adult ≥ 18
years), by whether the telemedicine consultant is infec-
tious diseases trained or not, by infection type, by type
of telehealth/telemedicine intervention (e.g., face-to-face,
asynchronous), by study location in the USA versus non-
US study location, by number of ID consultations (i.e.,
days), and by culture or laboratory-confirmed infection
versus presumed infection. Qualitative synthesis will be
performed if there are too few studies.
For each outcome, if clinical and methodological het-
erogeneity are sufficient, meta-analysis will be performed
using either fixed or random effect models [13]. If more
than 10 studies are included in the meta-analysis for a
particular outcome, we will investigate for publication
bias using standard methodologies [14].
We will also perform a descriptive review of the con-
textual use of telemedicine, including infection type and
screening criteria for telemedicine enrollment.
Reporting
The findings of this review will be published in accordance
with PRISMA-P guidelines [10] (see Additional file 1).
Discussion
Infectious diseases are a major source of morbidity and
mortality in the USA and abroad. The field of ID has diffi-
culty recruiting new physicians, with 51% of fellowship
programs not filling in 2015 [5, 6]. As such, strategies are
urgently needed to increase access to ID expertise to im-
prove patient outcomes. Our study will systematically re-
view and analyze the evidence for the use of telemedicine
for infectious diseases to help determine whether it is an
appropriate medium for dissemination of ID expertise. If
our study shows benefit for telemedicine as a means of
managing infectious diseases, it will be a prime research
target for dissemination and implementation research.
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